New tech addresses manufacturing bottlenecks in a lifesaving blood cancer treatment

Relapsed B-cell ALL is the leading cause of cancer-related deaths in children and young adults. UniSA research has shown the potential of new microfluidic technology, to improve the CAR T-cell manufacturing process by efficiently removing contaminating cancerous cells and other large white blood cells – potentially leading to greater access and lower costs of treatment. 

Read More